InStride Health Gains $30 Million Funding To Enhance Pediatric Mental Health Services

In a significant development for mental health care, InStride Health has successfully secured an oversubscribed $30m in its series B funding round, elevating its total funding to an impressive $56m. This financial infusion is earmarked for the expansion of the company's specialized treatment offerings for pediatric anxiety and obsessive-compulsive disorder (OCD), alongside investments in clinical quality and market penetration. The round saw participation from existing investors .406 Ventures, Valtruis, Mass General Brigham Ventures, and Hopelab Foundation, with General Catalyst also joining the ranks.

General Catalyst Managing Director Holly Maloney lauded InStride Health for its pivotal role in broadening access to affordable, high-quality mental healthcare services. With an alarming statistic indicating that approximately one-third of US youth will encounter an anxiety or OCD disorder by the age of 18, InStride Health's mission to bridge the current treatment gap is more crucial than ever. The company distinguishes itself by accepting major insurance plans and offering evidence-based care that commences within one to four weeks of approval.

The treatment programs at InStride Health, spanning from four months to a year, are meticulously designed to equip patients with the skills necessary for independent living. A unique aspect of their approach is the collaboration of multidisciplinary care teams comprising a psychiatrist, therapist, and exposure coach who collectively support the patient throughout their treatment journey in both clinical and real-world settings.

Furthermore, InStride Health actively engages in strategic partnerships with educational institutions, physicians, and referring providers to ensure a holistic care model. Manuela Villa, a clinician at Boston Children's Hospital, commended InStride for its innovative and evidence-based care approach coupled with its strategic partnership model. The company's commitment to measuring outcomes and making data-driven treatment decisions stands as a testament to its dedication to transparency and achieving lasting results.

Patients undergoing treatment at InStride Health report significant improvements in anxiety levels, functional impairment, and depression. Additionally, there is a noteworthy decrease in family accommodation and caregiver strain, as observed by parents. Co-founder and CEO John Voith expressed the company's ambition to extend its specialty clinical services to all individuals in need.

InStride Health specializes in outpatient care for pediatric anxiety and OCD, grounded on evidence-based treatments such as cognitive-behavioral therapy and acceptance and commitment therapy. With its acceptance of major insurance plans across multiple states, InStride Health is poised to make a substantial impact on mental health care accessibility and quality.